Nakao Masashi, Muramoto Yousuke, Hisadome Motoko, Yamano Naoko, Shoji Mami, Fukushima Yumi, Saruwatari Junji, Nakagawa Kazuko
Division of Pharmacology and Therapeutics, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Oe-honmachi 5-1, Kumamoto, 862-0973, Japan.
Eur J Clin Pharmacol. 2007 Apr;63(4):345-53. doi: 10.1007/s00228-006-0253-5. Epub 2007 Feb 13.
Shoseiryuto (TJ-19) contains eight herbal components, including Ephedra sinica, and has been used for treating asthma and allergic rhinitis in Asian countries for several centuries. In this study, we investigated the potential herb-drug interaction of TJ-19 in healthy volunteers and attempted to ascertain whether or not the interaction might be affected by the cytochrome P450 (CYP) 2D6 genotype.
We assessed the effect of TJ-19 on the activities of CYP1A2, CYP2D6, CYP3A, xanthine oxidase (XO), and N-acetyltransferase 2 (NAT2) in 37 healthy subjects. The subject pool consisted of 19 extensive metabolizers (EMs) with CYP2D6*Wild/Wild, and 18 intermediate metabolizers (IMs) with CYP2D610/*10. The baseline activities of five enzymes were ascertained by their respective urinary metabolic ratios from an 8-h urine sample, after an oral 150-mg and 30-mg dose of caffeine and dextromethorphan were administrated, respectively. Thereafter, the subjects received 4.5 g of TJ-19 twice daily for 7 days, and underwent the same phenotyping test on postdose day 7.
The activities of all enzymes examined did not differ before or after the 7-day administration of TJ-19. Consequently, the influence of the CYP2D6 genotype on the herb-drug interaction remained unsolved.
Our results indicate that TJ-19 at the generally recommended dosage is unlikely to cause pharmacokinetic interaction with co-administered medications primarily dependent on the CYP1A2, CYP2D6, CYP3A, XO, and NAT2 pathways for elimination.
柴芍六君子汤(TJ - 19)含有包括麻黄在内的八种草药成分,在亚洲国家已用于治疗哮喘和过敏性鼻炎几个世纪。在本研究中,我们调查了TJ - 19在健康志愿者中的潜在药草 - 药物相互作用,并试图确定这种相互作用是否可能受细胞色素P450(CYP)2D6基因型的影响。
我们评估了TJ - 19对37名健康受试者中CYP1A2、CYP2D6、CYP3A、黄嘌呤氧化酶(XO)和N - 乙酰转移酶2(NAT2)活性的影响。受试者群体包括19名CYP2D6 *野生/*野生的广泛代谢者(EMs)和18名CYP2D6 *10/*10的中间代谢者(IMs)。在分别口服150 mg和30 mg咖啡因及右美沙芬后,通过8小时尿液样本中各自的尿代谢比值确定五种酶的基线活性。此后,受试者每天两次接受4.5 g TJ - 19,共7天,并在给药后第7天进行相同的表型测试。
在7天的TJ - 19给药前后,所有检测酶的活性均无差异。因此,CYP2D6基因型对药草 - 药物相互作用的影响仍未解决。
我们的结果表明,按一般推荐剂量使用的TJ - 19不太可能与主要依赖CYP1A2、CYP2D6、CYP3A、XO和NAT2消除途径的联合用药发生药代动力学相互作用。